VABOMERE™
meropenem and vaborbactam
for injection (4 g)

ORDER SHEET

Two vials = 4 g dose

VABOMERE™ 4 g (2 g meropenem and 2 g vaborbactam)

INDICATION	VABOMERE™ (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: *Escherichia coli, Klebsiella pneumoniae,* and *Enterobacter cloacae species* complex.
CONTRAINDICATIONS	VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
NDC NO.	NDC 65293-009-06
HOW SUPPLIED	VABOMERE is supplied as a white to light yellow sterile powder for constitution in single-dose, clear glass vials that contain 2 grams of VABOMERE. Each vial contains 1 gram of meropenem (equivalent to 1.14 grams of meropenem trihydrate), 1 gram of vaborbactam, and 0.575 gram of sodium carbonate. VABOMERE cartons contain 6 vials.
WEIGHT	Carton: 0.93 lb/422.79 g
DIMENSIONS	Carton: 5.57 x 3.92 x 3.48 in (LxWxH)
ORDERING	VABOMERE is a wholesaler-stocked product. Please use standard ordering procedure through your wholesaler. If product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next Day Saver from a MDCO primary distribution provider by calling your wholesaler's customer service number listed below. • **AmerisourceBergen Customer CARE: (844) 222-2273** • **Cardinal Health Customer Service: (800) 926-3161** • **H. D. Smith Customer Service: (800) 628-2977** • **McKesson Customer Support: (855) 625-4677** • **Morris & Dickson Customer Service: (800) 388-3833**
STORAGE	Store VABOMERE vials at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F)

For Medical Information, please call 1-844-633-6568.

Please see reverse side for Important Safety Information.

Melinta THERAPEUTICS
The Antibiotics Company

INDICATIONS AND USAGE

VABOMERE™ (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: *Escherichia coli, Klebsiella pneumoniae,* and *Enterobacter cloacae species* complex.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

Contraindications

VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.

Warnings and Precautions

- Hypersensitivity reactions were reported in patients treated with VABOMERE in the clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving therapy with beta-lactam antibacterial drugs. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam antibacterial drug. If an allergic reaction to VABOMERE occurs, discontinue the drug immediately.
- Seizures and other adverse Central Nervous System (CNS) experiences have been reported during treatment with meropenem, which is a component of VABOMERE. Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity.
- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including VABOMERE, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against *C. difficile* may need to be discontinued.
- The concomitant use of VABOMERE and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. If administration of VABOMERE is necessary, consider supplemental anticonvulsant therapy.
- In patients with renal impairment, thrombocytopenia has been observed in patients treated with meropenem, but no clinical bleeding has been reported.
- Alert patients receiving VABOMERE on an outpatient basis regarding adverse reactions such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment.
- Prescribing VABOMERE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of drug-resistant bacteria.
- As with other antibacterial drugs, prolonged use of VABOMERE may result in overgrowth of nonsusceptible organisms.

Adverse Reactions

The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.

Reference: Vabomere [package insert]. Parsippany, NJ: The Medicines Company; 2017.

Melinta THERAPEUTICS The Antibiotics Company

VABOMERE™
meropenem and vaborbactam
for injection (4 g)